By Caroline Humer NEW YORK (Reuters) - Hospitals and health insurers are gaining confidence that their nightmare scenario - millions of Americans instantly losing health insurance once President-elect Donald Trump delivers on a promise to "repeal and replace" Obamacare - is looking more like a bad dream than becoming reality. The early view from the healthcare sector still includes an end eventually to President Obama's signature health program. Trump tapped Republican Representative Tom Price, an orthopedic surgeon who drafted legislation years ago to replace the Affordable Care Act (ACA), as head of the U.S. Department of Health and Human Services.
Medical Malpractice
Tuesday, November 29, 2016
Health industry breathes easier as post-Obamacare path stabilizes
Monday, November 28, 2016
Flu - or flu vaccine - in pregnancy not tied to autism in kids
Thursday, November 17, 2016
Britain seeks to curb pollution by small-scale power plants
Britain plans to curb health damaging air pollution with emissions standards for small-scale power plants used to generate back-up electricity at short notice and to stem the rising use of diesel generators. The Department for Environment, Food and Rural Affairs (DEFRA) suggests plants producing 1-50 megawatts (MW) of electricity should be subject to new rules to cut emissions of harmful pollutants such as nitrogen dioxide. "The combined impact of Nitrogen Dioxide (NO2) and Particulate Matter (PM) pollution in the UK is estimated to lead to the equivalent of approximately 50,000 premature deaths per year, at a cost of around 30 pounds billion per year," DEFRA said as it launched the consultation this week.
Monday, November 14, 2016
'Terrible time'
Monday, November 7, 2016
Gut bacteria 'may help drugs fight cancer'
Cancer survivor: 'I was sacked for having lymphoma'
After $195 million in talc verdicts, J&J strives to change court
After a $67.5 million jury verdict against Johnson & Johnson on Oct. 27 marked its third straight trial defeat in an onslaught of lawsuits claiming its talc-based products cause ovarian cancer, the company is hoping to reverse the trend by having the cases heard in a different court. All three awards, totaling around $195 million, were handed down in state court in St. Louis, Missouri, with the same judge presiding. The plaintiffs claim studies show J&J's Baby Powder and Shower to Shower products, when used in the vaginal area, increase the risk of ovarian cancer.